Skip to content
Screener

Lifecore Biomedical, Inc. LFCR Q2 2026 earnings

Reported November 6, 2025 · After market close

Revenue$31.1MBeat by $4.6M
EPS-$0.29Beat by $0.01
Revenue estimate$26.5M
EPS estimate-$0.30

Next report

Date not yet announced

Financials

Q2 2026

Income statement

See full
Revenue$31.1M-4.5%
Gross profit$7.8M-29.7%
Operating income-$3.1M-56.6%
Net income-$10.0M-52.0%
EPS (diluted)-$0.29-16.0%

Balance sheet

See full
Cash & equivalents$18.9M+99.4%
Total debt$8.4M-92.4%
Total equity-$10.5M-168%
Total assets$235.2M-7.9%

Cash flow

See full
Operating cash flow$1.8M+129%
CapEx$1.7M-28.8%
Free cash flow$25.0K+100%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$295.98M+29.5%
Enterprise value$285.57M-13.6%

Returns & leverage

See full
Current ratio2.8×+0.5×

Segments

By product

See full
CDMO$21.7M-15.1%
HA manufacturing$9.4M+34.6%

By segment

See full
Reportable Segment$31.1M-4.5%

FAQ

When did Lifecore Biomedical, Inc. report Q2 2026 earnings?
Lifecore Biomedical, Inc. (LFCR) reported Q2 2026 earnings on November 6, 2025 after market close.
What were Lifecore Biomedical, Inc.'s Q2 2026 revenue and EPS?
Lifecore Biomedical, Inc. reported revenue of $31.1M and eps of $-0.29 for Q2 2026.
Did Lifecore Biomedical, Inc. beat estimates in Q2 2026?
Revenue beat the consensus estimate of $26.5M by $4.6M. EPS beat the consensus estimate of $-0.30 by $0.01.
Where can I find Lifecore Biomedical, Inc.'s Q2 2026 SEC filings?
You can read the 8-K earnings release (0001005286-25-000146) and the 10-Q periodic report (0001005286-25-000148) directly on SEC EDGAR. The filing index links above go to sec.gov.